Comparing the effects of prescribed safer opioid supply and methadone in Ontario, Canada

Click on image to expand.

Background

Prescribed safer opioid supply (SOS) programs are novel harm reduction interventions.

Objective

This study examined health outcomes among people receiving SOS over time and relative to a similar group of people receiving methadone.

Methods

We conducted a population-based cohort study among new SOS and methadone recipients in Ontario, Canada, who commenced treatment between Jan 1, 2016 and Dec 31, 2021.

Results

Of 991 new SOS recipients and 25,116 new methadone recipients, 856 individuals from each group were matched. Within-group analysis showed significant improvements among SOS recipients across multiple health outcomes, with similar findings for methadone. In the between-group analysis, SOS recipients had higher hazards of opioid toxicity, emergency visits, and hospitalizations, no difference in infection rates, and were less likely to discontinue treatment. When discontinuation was not censored, differences between groups disappeared for all outcomes except opioid toxicity.

Conclusion

SOS and methadone were associated with improvements in health outcomes, including reduced opioid toxicities and health-care use, in the year after treatment initiation. The findings suggest SOS programs play an important, complementary role to traditional opioid agonist treatment in expanding the options available to support people who use drugs.

Additional Resources

Citation

Gomes T, McCormack D, Kolla G, Young S, Bayoumi AM, Smoke A, Li P, Antoniou T. (2025). Comparing the Impact of Prescribed Safer Opioid Supply and Methadone on Clinical Outcomes in Ontario: A Population-Based Matched Cohort Study. The Lancet Public Health.

Date Released:

April 22, 2025

Related Research

Journal Article

Initiation of opioid agonist treatment following hospital-treated opioid toxicities and the risk of repeat events in Ontario, Canada

November 18, 2025